Regional distribution of vasoactive intestinal peptide in brains from normal and parkinsonian subjects

[1]  P. Hof,et al.  Autoradiographic mapping of [mono[125I]iodo-Tyr10, MetO17]vasoactive intestinal peptide binding sites in the rat brain , 1987, Neuroscience.

[2]  W. Rostène,et al.  Characterization and autoradiographic distribution of vasoactive intestinal peptide binding sites in the rat central nervous system , 1986, Brain Research.

[3]  Y. Agid,et al.  Neuropeptides and Parkinson's disease. , 1986, Progress in brain research.

[4]  J. Morrison,et al.  VIP neurons in the neocortex , 1985, Trends in Neurosciences.

[5]  W. Rostène.  Neurobiological and neuroendocrine functions of the vasoactive intestinal peptide (vip) , 1984, Progress in Neurobiology.

[6]  H. Arai,et al.  Somatostatin and vasoactive intestinal polypeptide in postmortem brains from patients with Alzheimer-type dementia , 1984, Neuroscience Letters.

[7]  F. Eckenstein,et al.  Two types of cholinergic innervation in cortex, one co-localized with vasoactive intestinal polypeptide , 1984, Nature.

[8]  F. E. Bloom,et al.  The distribution and morphological characteristics of the intracortical VIP-positive cell: An immunohistochemical analysis , 1984, Brain Research.

[9]  P. Gaspar,et al.  Biochemical neuropathology of Parkinson's disease. , 1984, Advances in neurology.

[10]  Yves Agid,et al.  A subcortico-cortical cholinergic system is affected in Parkinson's disease , 1983, Brain Research.

[11]  Y. Agid,et al.  Parkinson's disease affects differently Met5- and Leu5-enkephalin in the human brain , 1983, Brain Research.

[12]  I. Ferrier,et al.  Neuropeptides in Alzheimer type dementia , 1983, Journal of the Neurological Sciences.

[13]  Y. Agid,et al.  Somatostatin and dementia in Parkinson's disease , 1983, Brain Research.

[14]  Y. Agid,et al.  Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease , 1983, Brain Research.

[15]  Y. Agid,et al.  Thyrotropin releasing hormone content is unchanged in brains of patients with Parkinson disease , 1983, Neuropeptides.

[16]  Y. Agid,et al.  Decrease of substance P-like immunoreactivity in the substantia nigra and pallidum of parkinsonian brains , 1983, Brain Research.

[17]  S. Hunt,et al.  Extrahypothalamic vasopressin is unchanged in Parkinson's disease and Huntington's disease , 1982, Brain Research.

[18]  C. Köhler.  Distribution and morphology of vasoactive intestinal polypeptide-like immunoreactive neurons in regio superior of the rat hippocampal formation , 1982, Neuroscience Letters.

[19]  Y. Agid,et al.  CCK-8-immunoreactivity distribution in human brain: selective decrease in the substantia nigra from parkinsonian patients , 1982, Brain Research.

[20]  Y. Agid,et al.  Muscarinic binding and choline acetyltransferase activity in Parkinsonian subjects with reference to dementia , 1982, Brain Research.

[21]  F. Bloom,et al.  Vasoactive intestinal polypeptide induces glycogenolysis in mouse cortical slices: a possible regulatory mechanism for the local control of energy metabolism. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[22]  E. Perry,et al.  Neuropeptides in Alzheimer's disease, depression and schizophrenia A post mortem analysis of vasoactive intestinal peptide and cholecystokinin in cerebral cortex , 1981, Journal of the Neurological Sciences.

[23]  D. Coy,et al.  Solid-phase synthesis of porcine vasoactive intestinal peptide. , 2009, International journal of peptide and protein research.

[24]  Y Agid,et al.  Is the mesocortical dopaminergic system involved in Parkinson disease? , 1980, Neurology.

[25]  P. Emson,et al.  Reduced corticol choline acetyltransferase activity in senile dementia of Alzheimer type is not accompanied by changes in vasoactive intestinal polypeptide , 1980, Brain Research.

[26]  J. Mcculloch,et al.  Cerebral circulatory and metabolic effects of vasoactive intestinal polypeptide. , 1980, The American journal of physiology.

[27]  E. Zimmerman,et al.  Vasoactive intestinal polypeptide (VIP) in mouse and rat brain: An immunocytochemical study , 1980, Brain Research.

[28]  A. Björklund,et al.  Distribution of vasoactive intestinal polypeptide in the rat and mouse brain , 1979, Neuroscience.

[29]  P. Emson,et al.  Vasoactive intestinal polypeptide (VIP): distribution in normal human brain and in Huntington's disease , 1979, Brain Research.

[30]  A. Hakim,et al.  Dementia in Parkinson disease , 1979, Neurology.

[31]  J. Phillis,et al.  Vasoactive intestinal polypeptide excitation of central neurons. , 1978, Canadian journal of physiology and pharmacology.

[32]  T. Jessell,et al.  Vasoactive intestinal polypeptide (VIP): vesicular localization and potassium evoked release from rat hypothalamus , 1978, Brain Research.

[33]  H. Vaudry,et al.  Biological and radioimmunological evidence for melanocyte stimulating hormones (MSH) of extrapituitary origin in the rat brain. , 1978, Neuroendocrinology.

[34]  T. Hökfelt,et al.  Vasoactive intestinal polypeptide and the nervous system: Immunohistochemical evidence for localization in central and peripheral neurons, particularly intracortical neurons of the cerebral cortex , 1977, Neuroscience Letters.

[35]  S. Said,et al.  Vasoactive intestinal polypeptide in brain: localization in and release from isolated nerve terminals. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[36]  R. Rosenberg,et al.  VASOACTIVE INTESTINAL POLYPEPTIDE IN BRAIN SYNAPTOSOMES , 1976, The Lancet.

[37]  M. Mesulam,et al.  Acetylcholinesterase-rich projections from the basal forebrain of the rhesus monkey to neocortex , 1976, Brain Research.

[38]  K. Lloyd,et al.  DISTRIBUTION OF CHOLINE ACETYLTRANSFERASE AND GLUTAMATE DECARBOXYLASE WITHIN THE SUBSTANTIA NIGRA AND IN OTHER BRAIN REGIONS FROM CONTROL AND PARKINSONIAN PATIENTS , 1975, Journal of neurochemistry.

[39]  V. Mutt,et al.  Polypeptide with Broad Biological Activity: Isolation from Small Intestine , 1970, Science.

[40]  O. Hornykiewicz.  Dopamine (3-hydroxytyramine) and brain function. , 1966, Pharmacological reviews.

[41]  F. Greenwood,et al.  Preparation of Iodine-131 Labelled Human Growth Hormone of High Specific Activity , 1962, Nature.

[42]  M. Jacob,et al.  Uncoupling of oxidative phosphorylation by cadmium ion. , 1956, The Journal of biological chemistry.